Eight institutional shareholders hold more than 5% of Fluidigm ahead of its Nasdaq flotation.
Fluidigm, a US-based provider of healthcare products, plans to raise $86.25m in its Nasdaq flotation.
The company uses nanotechnology to control valves and fluids at a small scale in the biotechnology industry.
Fluidigm made a $12.6m loss on $23.2m of revenues in the first nine months of the year compared to a $14.25m loss on $17.8m turnover in the same period last year.
Investment banks Deutsche Bank and Piper Jaffray are co-lead underwriters of the initial public offering (IPO).
There are eight institutional shareholders with more than 5% of Fluidigm, according to its regulatory filing.
EuclidSR Partners, a joint venture between venture capital (VC) firm Euclid Partners and drugs company GlaxoSmithKline’s SR One corporate venturing unit, owns 7.1%; the BioMedical Sciences Investment Fund, which is managed by EDB Investments, a Singapore state investment division, holds 13%; VC firms Versant Ventures, formerly called Institutional Venture Partners, Alloy Ventures and InterWest Venture Partners own 8.5%, 5.5% and 5.6% respectively; and fund managers Lehman Brothers, Fidelity and Smallcap World hold 5.3%, 9.1% and 5.3% respectively.
Founded in 1999, Fluidigm closed its series E round in January 2007 at $37m, and news provider VentureWire said it raised a further $7.5m in 2009 after pulling its first attempt at an IPO the year before. Between launch in 1999 and its series D round in 2005, Fluidigm raised $59m, VentureWire said.
